Our Pipeline

A robust pipeline of ADCs for the treatment of hematological cancers and solid tumors.

Strategic target selection for pyrrolobenzodiazepine (PBD)-based antibody drug conjugates (ADCs) and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematologic and solid tumor cancers with significant unmet need.

ADCT has multiple PBD-based ADCs in ongoing clinical trials and numerous preclinical ADCs in development.

The agents represented in this pipeline chart are investigational. Efficacy and safety have not yet been established.